Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 24, Issue 3, 2012, Pages 319-326

  Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

biologic; remission; rheumatoid arthritis; TNF inhibitors; treatment

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE;

BIOLOGICAL THERAPY; CLINICAL EVALUATION; CLINICAL STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; JOINT INJURY; LONG TERM CARE; LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SEPSIS; TREATMENT PLANNING; TREATMENT WITHDRAWAL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOLOGIC FACTORS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863403514     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283524e4c     Document Type: Review

References (23)

1. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69:631-637.
2. Aletaha D, Neogi T, Silman A, et al. 2010 Rheumatoid arthritis classification criteria. Arthritis Rheum 2010; 62:2569-2581
3. Felson DT, Smolen JS, Wells G, et al. American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70:404-413
4. Singh J. 2012 Update of the 2008 ACR recommendations for the treatment of RA [abstract]. Arthritis Rheum 2011; 63(Suppl):2011
5. Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 2011; 13 (Suppl 1):S3.
6. Smolen JS, Emery P. Infliximab: 12 years of experience. Arthritis Res Ther 2011; 13 (Suppl 1):S2.
7. Lipsky PE, van der Heijde DMFM, St Clair EW, et al. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group: infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343:1594-1602
8. Smolen JS, van der Heijde D, St Clair EW, et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group: predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab. Results from the ASPIRE trial. Arthritis Rheum 2006; 54:702-710
9. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372:375-382
10. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26-37 (Pubitemid 43122183)
11. Koike T, Harigai M, Tanaka Y, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009; 36:898-906
12. Tanaka Y, Takeuchi T, Inoue E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: 1 year clinical and radiographic outcomes (RECONFIRM-II). Mod Rheum 2008; 18:146-152
13. Takeuchi T, Yamanaka H, Tanaka Y, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol 2008; 18:447-454
14. Weinblatt ME, Bathon JM, Kremer JM, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and long-standing rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010 [Epub ahead of print].
15. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52:27-35 (Pubitemid 40129229)
16. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized controlled trial. Arthritis Rheum 2005; 52:3381-3390 (Pubitemid 41612204)
17. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis, RRR (remission induction by remicade in RA) study. Ann Rheum Dis 2010; 69:1286-1291.
18. Arthur Kavanaugh, Emery P, Fleischman R, et al. Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebocontrolled trial [abstract]. ACR2011;1699
19. Detert J, Bastian H, Listing J, et al. Efficacy of an induction therapy with adalimumab plus methotrexate versus methotrexate monotherapy in recent onset rheumatoid arthritis: an investigator initiated randomized controlled trial [abstract]. ACR2011;1697
20. Tanaka Y, Hirata S, Nawata M, et al. Discontinuation of adalimumab without functional and structural progress after attaining remission in patients with rheumatoid arthritis (an interim report of HONOR study) [abstract]. ACR2011;2468
21. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2008; 58 (2 Suppl):S126-S135
22. van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007; 56:2129-2134 (Pubitemid 47173559)
23. Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008; 18:460-464.